123836-99-7

Upstream product

• 123837-02-5 3-<3-<1-phenyl-1-(tetrahydropyranyloxy)methyl>-1,2,4-oxadiazol-5-yl>quinuclidine 
• 123837-01-4 α-(tetrahydropyranyloxy)phenylacetamide oxime 
• 64133-02-4 α-(tetrahydropyranyloxy)benzyl cyanide 
• 38206-86-9 methyl quinuclidine-3-carboxylate 
• 123837-25-2 3-<3-(1-hydroxy-1-phenylmethyl)-1,2,4-oxadiazol-5-yl>quinuclidine 

Downstream Products

• 123836-90-8 3-<3-(1,1-diphenyl-1-hydroymethyl)-1,2,4-oxadiazol-5-yl>quinuclidine 
• 791-28-6 Triphenylphosphine oxide 

Relevant academic research and scientific papers

Squalene synthetase inhibitors

Compounds of structural formula (I): STR1 are squalene synthestase inhibitors useful in inhibiting the biosynthesis of cholesterol in the treatment of hypercholesterolemia and related disorders.

Novel Quinuclidine-Based Ligands for the Muscarinic Cholinergic Receptor

Recent clinical studies on Alzheimer's patients have implied that only agents displaying high efficacy at the cortical muscarinic receptor have yielded encouraging results.This paper describes the design, synthesis, and biochemical characterization of nov

Lipophilic oxadiazoles

Oxadiazoles of formula I wherein one of X, Y and Z is an oxygen atom and the other two are nitrogen atoms, and the dotted circle represents aromaticity (two double bonds) thus forming a 1,3,4-oxadiazole or 1,2,4-oxadiazole nucleus; R1 represents a non-aromatic azacyclic or azabicyclic ring system; and R2 represents an optionally substituted saturated hyrocarbon group having at least three carbon atoms, or unsaturated hydrocarbon group having at least 6 carbon atoms, have particularly advantageous selective properties for use in the treatment and/or prevention of neurodegenerative diseases.